Antenatal magnesium sulfate to prevent cerebral palsy.

Keir, AK; Shepherd, E; McIntyre, S; Rumbold, A; Groves, C; Crowther, C; Callander, EJ

Antenatal magnesium sulfate to prevent cerebral palsy.

Keir, AK Shepherd, E McIntyre, S Rumbold, A Groves, C Crowther, C Callander, EJ

Permalink

Publisher:: BMJ PUBLISHING GROUP
Publication Type:: Journal Article
Citation:: Arch Dis Child Fetal Neonatal Ed, 2022, 107, (2), pp. 225-227
Issue Date:: 2022-03

Closed Access

	Filename	Description	Size
	225.full.pdf		367.9 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Keir, AK
dc.contributor.author	Shepherd, E
dc.contributor.author	McIntyre, S
dc.contributor.author	Rumbold, A
dc.contributor.author	Groves, C
dc.contributor.author	Crowther, C
dc.contributor.author	Callander, EJ
dc.date.accessioned	2023-02-10T01:43:15Z
dc.date.available	2021-06-17
dc.date.available	2023-02-10T01:43:15Z
dc.date.issued	2022-03
dc.identifier.citation	Arch Dis Child Fetal Neonatal Ed, 2022, 107, (2), pp. 225-227
dc.identifier.issn	1359-2998
dc.identifier.issn	1468-2052
dc.identifier.uri	http://hdl.handle.net/10453/166033
dc.description.abstract	Magnesium sulfate given to women before birth at <30 weeks' gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks' gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	BMJ PUBLISHING GROUP
dc.relation	http://purl.org/au-research/grants/nhmrc/1159536
dc.relation.ispartof	Arch Dis Child Fetal Neonatal Ed
dc.relation.isbasedon	10.1136/archdischild-2021-321817
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1114 Paediatrics and Reproductive Medicine
dc.subject.classification	Pediatrics
dc.subject.mesh	Calcium Channel Blockers
dc.subject.mesh	Cerebral Palsy
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Infant, Newborn
dc.subject.mesh	Infant, Premature
dc.subject.mesh	Infant, Premature, Diseases
dc.subject.mesh	Magnesium Sulfate
dc.subject.mesh	Pregnancy
dc.subject.mesh	Premature Birth
dc.subject.mesh	Humans
dc.subject.mesh	Cerebral Palsy
dc.subject.mesh	Premature Birth
dc.subject.mesh	Infant, Premature, Diseases
dc.subject.mesh	Magnesium Sulfate
dc.subject.mesh	Calcium Channel Blockers
dc.subject.mesh	Pregnancy
dc.subject.mesh	Infant, Newborn
dc.subject.mesh	Infant, Premature
dc.subject.mesh	Female
dc.title	Antenatal magnesium sulfate to prevent cerebral palsy.
dc.type	Journal Article
utslib.citation.volume	107
utslib.location.activity	England
utslib.for	1114 Paediatrics and Reproductive Medicine
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2023-02-10T01:43:13Z
pubs.issue	2
pubs.publication-status	Published
pubs.volume	107
utslib.citation.issue	2

Abstract:

Magnesium sulfate given to women before birth at <30 weeks' gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks' gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/166033